Intellia Therapeutics (NTLA) EBT Margin: 2015-2025
Historic EBT Margin for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to -760.14%.
- Intellia Therapeutics' EBT Margin rose 69577.00% to -760.14% in Q3 2025 from the same period last year, while for Sep 2025 it was -774.19%, marking a year-over-year increase of 35860.00%. This contributed to the annual value of -840.50% for FY2024, which is 44264.00% up from last year.
- Latest data reveals that Intellia Therapeutics reported EBT Margin of -760.14% as of Q3 2025, which was down 5.54% from -720.21% recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' EBT Margin ranged from a high of 6,647.52% in Q4 2023 and a low of -23,881.33% during Q3 2021.
- Moreover, its 3-year median value for EBT Margin was -793.10% (2023), whereas its average is -251.98%.
- In the last 5 years, Intellia Therapeutics' EBT Margin slumped by 2,375,604bps in 2021 and then spiked by 2,310,050bps in 2022.
- Intellia Therapeutics' EBT Margin (Quarterly) stood at -621.69% in 2021, then slumped by 14,994bps to -771.63% in 2022, then skyrocketed by 741,915bps to 6,647.52% in 2023, then slumped by 762,481bps to -977.29% in 2024, then spiked by 69,577bps to -760.14% in 2025.
- Its EBT Margin was -760.14% in Q3 2025, compared to -720.21% in Q2 2025 and -674.83% in Q1 2025.